Arrowhead to Present at Upcoming Conferences

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the Company will present at upcoming investor and scientific conferences.

Investor Conferences

  • Jefferies 2014 Global Healthcare Conference on Thursday, Nov. 20 at 12:20 p.m. GMT in London
  • 7th Annual 2014 Deutsche Bank BioFEST on Monday, Dec. 1, at 11:35 a.m. EST in Boston
  • 26th Annual Piper Jaffray Healthcare Conference on Wednesday, Dec. 3, at 3 p.m. EST in New York

Investors may access a live and archived audio webcast of these presentations on the Company's website at http://ir.arrowheadresearch.com/events.cfm.

Scientific Conferences

  • 15th Annual EuroTIDES meeting on Wednesday, Nov. 19, at 5 p.m. CET in Berlin

About Arrowhead Research Corporation

Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary Dynamic Polyconjugate delivery platform to develop targeted drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Arrowhead’s pipeline includes ARC-520 for chronic hepatitis B virus, ARC-AAT for liver disease associated with Alpha-1 antitrypsin deficiency, and partner-based programs in obesity and oncology.

For more information please visit http://www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list and receive news directly, please visit

http://ir.arrowheadresearch.com/alerts.cfm.

Source: Arrowhead Research Corporation

Contacts:

Company:
Arrowhead Research Corporation
Vince Anzalone, CFA
626-304-3400
ir@arrowres.com
or
Investor Relations:
The Trout Group
Lauren Glaser
646-378-2972
ir@arrowres.com
or
Media:
Russo Partners
Martina Schwarzkopf, Ph.D.
212-845-4292
martina.schwarzkopf@russopartnersllc.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.